Physician profile
Le L Luu
NPI 1295767770
$494.14
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $124.96 | 2019 | |
| Novo Nordisk INC | $65.87 | 2019 | |
| Amgen INC. | $63.40 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $52.14 | 2019 | |
| Janssen Pharmaceuticals, INC | $33.13 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $28.37 | 2019 | |
| Allergan, INC. | $21.62 | 2019 | |
| Glaxosmithkline, LLC. | $19.07 | 2019 | |
| Ethicon US, LLC | $16.68 | 2019 | |
| Hikma Pharmaceuticals USA | $16.32 | 2019 | |
| Astellas Pharma US INC | $15.16 | 2019 | |
| Sanofi Pasteur INC. | $14.76 | 2019 | |
| Pfizer INC. | $13.87 | 2019 | |
| Dynavax Technologies Corporation | $8.79 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Le Luu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.